Globe News Wire
02 Feb 2026, 15:30 UTC · 31w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
The global infant nutrition market is projected to grow from USD 61.03 billion in 2025 to USD 162.08 billion by 2035, representing a CAGR of 10.26%. — Strong long-term growth projections for the sector indicate significant expansion opportunities for companies specializing in this space.
+0.60The industry is shifting toward 'premiumization,' where revenue growth is decoupled from declining birth rates through high-margin, clinically-proven, and medical-grade nutrition. — This shifts the investment thesis from volume-based growth to value-based growth, benefiting specialized leaders like Danone and Abbott over generalists.
+0.50Reckitt is strategically divesting Mead Johnson (Enfamil) by late 2025, signaling a broader trend of generalist players exiting the market. — A major corporate divestment suggests a sectoral consolidation that favors dedicated nutrition science firms over diversified conglomerates.
+0.40Continue reading
5 related stories
Search tags
The FDA's National Strategy, released in January 2025, has led to aggressive enforcement and warning letters to major retailers including Walmart, Target, Kroger, and Albertsons. — Increased regulatory scrutiny and enforcement regarding recalls create operational risks and potential legal liabilities for both manufacturers and retailers.
-0.30Hypermarkets and supermarkets remain the dominant distribution channel due to consumer preferences for physical verification of product safety and seals. — While reaffirming the strength of traditional retail, it suggests a slower-than-expected transition to e-commerce for this specific product category.
+0.10Which stocks this story touches
Reported a 17% sales surge in Specialized Nutrition in China, successfully defying demographic headwinds.
Winning with hypoallergenic and medical-grade solutions that command inelastic pricing power.
Secured a top-5 position in China through protein differentiation.
Reversed early-year slumps by leveraging proprietary HMO technology and R&D investments.
Received an FDA warning letter for failing to remove recalled products.
Received an FDA warning letter for failing to remove recalled products.
Received an FDA warning letter for failing to remove recalled products.
Received an FDA warning letter for failing to remove recalled products.
Benefiting from parents favoring physical retailers for trust and verification.
Strategically divesting its Mead Johnson business, signaling an exit from the specialized nutrition field.
[mutual] Both companies compete in the specialized and hypoallergenic infant nutrition segments.
[mutual] Both companies are leading players in the global infant nutrition market focusing on premiumization and medical nutrition.
[mutual] Both companies invest heavily in R&D to nutritionally mirror human breast milk in infant formula.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13h ago
[mutual] Both companies compete for market share in the infant nutrition market, specifically in China.
[b_to_a] Walmart acts as a retail distribution channel for infant nutrition brands.
[b_to_a] Walmart acts as a retail distribution channel for infant nutrition brands.
[b_to_a] Walmart acts as a retail distribution channel for infant nutrition brands.
